Placental metabolism and disease by Sobrevia, Luis
Accepted Manuscript
Placental metabolism and disease
Luis Sobrevia
PII: S0143-4004(18)31037-3
DOI: 10.1016/j.placenta.2018.09.001
Reference: YPLAC 3873
To appear in: Placenta
Please cite this article as: Sobrevia L, Placental metabolism and disease, Placenta (2018), doi: 10.1016/
j.placenta.2018.09.001.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 1
Editorial 
 
Placental metabolism and disease 
 
Introduction 5 
The placenta is recognised as an organ that plays a vital role as a metabolic and a 
physical barrier in the foetoplacental unit. Several metabolic substrates and other molecules 
cross the placenta from the mother to the foetus and vice versa. This physiological 
phenomenon is considered as a mechanism of communication between the mother and the 
foetus. The exchange of metabolic signals between the mother and the foetus is mutually 10 
beneficial and secures the development and growth of the foetus as well as the wellbeing of 
the mother during and after pregnancy. The primary cell types in the placenta are 
trophoblasts (which form the syncytiotrophoblasts) as well as the vascular endothelium and 
smooth muscle (forming the placental macrovascular and microvascular net). The 
architecture of these cells in the placenta imposes structural and metabolic barriers for the 15 
transfer of metabolic substrates (e.g. oxygen, D-glucose, amino acids and vitamins), 
hormones (e.g. thyroid hormones), toxins (e.g. carbon dioxide) and waste material. It is also 
an organ that transfers immunity and releases hormones (e.g. oestrogen, progesterone, 
placental lactogen and placental variant growth hormone (GH-V)) [1] and extracellular 
vesicles including nanovesicles (i.e. exosomes) into the foetal [2] and maternal [3] 20 
circulation. 
Pregnancy is a physiological phenomenon that could initiate in healthy women, thus 
leading to a healthy pregnancy and a healthy newborn and mother. However, women who 
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show pre-gestational diseases or metabolic disturbances develop a condition that results in 
an adverse outcome for the mother and the foetus. Further, pregnancy disorders such as 25 
preeclampsia and gestational diabetes mellitus (GDM) are associated with an adverse 
intrauterine environment for foetal development and growth. These pathological conditions 
result in altered foetoplacental vascular function and adverse newborn outcome, thereby 
making them prone to develop diseases in their childhood, adolescence and adulthood. It is 
worrying to know that the worldwide prevalence of type 1 (T1DM) and type 2 (T2DM) 30 
diabetes mellitus and obesity increased significantly in the last decade and at higher rates 
than before [4,5]. In developing countries like Chile in South America, the prevalence of 
diabetes mellitus increased to ∼44% in the last 6-7 years in women during their 
reproductive age [6]. Additionally, the prevalence of overweight (body mass index (BMI) 
25–29.9 kg/m2) and obesity (BMI ≥30 kg/m2) [5] in this group of women increased to ∼9% 35 
and ∼23%, respectively, during the same period [6]. Thus, a higher risk of an unhealthy 
pregnancy along with diabetes mellitus- and pre-gestational maternal obesity (PGMO)-
associated adverse outcomes (maternal, foetal, newborn, child and adult) in Chilean women 
(and worldwide) is likely. 
Patients who are obese and develop T2DM, with or without associated risk factors, 40 
are referred to as having ‘diabesity’ [7,8]. Patients with diabesity show an abnormal 
functioning of the cardiovascular system worsening its response to vasodilators (e.g. insulin 
and adenosine) compared with patients with obesity or T2DM only [8,9]. With regard to 
pre-GDM and obesity, GDM prevalence is also increasing worldwide. Thus, PGMO is a 
risk factor that could cause or associate with the GDM-related deleterious effects seen in 45 
the mother, foetus and newborn. However, it is unknown whether pregnant women with 
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PGMO, without T2DM or T1DM, who develop GDM (herein referred to as ‘gestational 
diabesity’) could differentially affect or worsen the vascular function in the human placenta 
caused by maternal obesity or GDM only. 
 50 
Contributions to the issue  
Common factors in preeclampsia, intrauterine growth restriction, GDM, PGMO and 
supraphysiological maternal gestational weight gain (spGWG) include altered transport of 
L-arginine and adenosine, modified nitric oxide (NO) synthesis and bioavailability, miss-
handling of magnesium (Mg2+) by the placental tissue and dyslipidaemia and an 55 
imbalanced redox state. In this special issue of Placenta, a series of review articles 
concerning various aspects associated with pregnancy and foetoplacental function in 
metabolic diseases is discussed. Professor David Hill (Canada) describes that placental 
lactogen and GH-V are factors involved in the foetal nutritional availability, thereby 
causing modifications in the insulin/insulin-like growth factor axis [10]. The latter is a 60 
concept that seems crucial in understanding the physiology and pathophysiology of the 
insulin signalling in the placental vasculature. Insulin resistance is seen in the mother and 
the foetus in GDM, and several essential signalling molecules associated with insulin 
receptor B involved in the downregulation of the insulin receptor substrates 1 and 2 – 
protein kinase B/Akt (Akt) branch have been reported [11,12]. Interestingly, increased GH-65 
V is associated with peripheral insulin resistance, a phenomenon likely counter-balanced by 
an expansion of maternal pancreatic β-cell mass. This review proposes that maternal 
obesity during pregnancy is a factor that induces trans-differentiation of pancreatic α to β 
cells, which could result in increased β-cell mass in diabetes during pregnancy. The latter is 
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a mechanism proposed to prevent the onset of gestational diabetes; however, because the 70 
lack of information addressing the effect of PGMO as an inductor of GDM in humans, this 
mechanism is still waiting for a proper characterisation in gestational diabesity. 
Presently, it is better known that maternal metabolic disorders during pregnancy 
correlated with modifications in the foetus and newborn, thereby resulting in the 
programming of adulthood health and disease. Dr Bredford Kerr and colleagues (Chile) 75 
proposed in their review that epigenetic modifications are capable of changing the 
expression of metabolism-related genes [13]. Modified expression of several genes in the 
human placenta associated with the transport and metabolism of nutrients, therefore 
affecting the foetal growth, is proposed to result from epigenetic mechanisms. Epigenetic 
changes include altered methylation of CpG dinucleotides, post-translational modifications 80 
of histones, methylation in CpH dinucleotides (where H is adenine, thymine or cytosine) 
and micro RNA (miRNA) expression. Interestingly, diseases during pregnancy, such as 
maternal dyslipidaemia, PGMO or maternal obesity resulting from spGWG, and GDM 
course with an altered uptake of essential metabolic substrates including L-arginine and 
adenosine thus alter the generation of NO in the placental vasculature [14-17]. Figure 1 85 
summarises the epigenetic modifications reported in the mother, placenta, newborn, 
childhood and adulthood in these metabolic alterations that occurred during pregnancy. 
Whether changes in the transport of metabolic substrates in the placenta are due to 
epigenetic modifications is not yet fully understood. 
Interestingly, aberrant expression of placental genes involved in oxidative stress and 90 
inflammation, among others, has been explained by epigenetic modifications [18,19]. The 
review by Professor Hillebrands and colleagues (The Netherlands) summarised the 
findings available in the literature, thus addressing the role of oxidative stress in 
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pregnancies with preeclampsia [20]. The role or involvement of superoxide anion, 
hydrogen peroxide and peroxynitrite is reported in the pathological placenta for each 95 
trimester of pregnancy. Placental adaptation to hypoxia and mechanisms regarding 
oxidative stress are described in this review. Additionally, understanding the genesis and 
causes of the generation of oxidative stress markers in preeclampsia will reach to a stage 
where associated biomarkers could be used as a tool to predict potential significant 
disturbances in the redox state in the placenta, which alter foetal development. 100 
Gasotransmitters are known for their role in regulating vascular tone in the placenta. 
Because oxidative stress is a condition that could result in abolishing the biological actions 
of NO, carbon monoxide and hydrogen sulphide, it is proposed that the bioavailability of 
these molecules could be altered in diseases, thereby affecting the function of the placenta.  
Hydrogen sulphide and NO not only regulate vascular tone but are also involved in 105 
immunological and angiogenic processes. These metabolic effects are in fact a topic 
touched in the review by Dr Faas and Professor Paul De Vos (The Netherlands), thus 
addressing the available literature about immune cells, specifically uterine natural killer 
(uNK) cells, and their role in the development of the placental bed [21]. These cells 
regulate the immune function in conjunction with macrophages, dendritic cells and mast 110 
cells in the placenta. Further, these cells modulate trophoblast invasion, angiogenesis and 
spiral artery remodelling, thus playing a pivotal role in preeclampsia where decreased 
trophoblast invasion and spiral artery remodelling are reported. Interestingly, this 
phenomenon is likely due to inhibition of matrix metalloproteinases resulting from the 
overexpression of the reversion-inducing cysteine-rich protein with Kazal motifs in the 115 
human placenta in preeclampsia [22]. 
Placental vasculogenesis is a physiological mechanism required in gestation, and it 
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could deviate from the normal at any time depending on the microenvironment in 
pregnancy. The review by Dr Azevedo Portilho and Dr Pelajo-Machado (Brazil) shows 
results in the mouse placenta where a putative haematopoietic foci in the placenta labyrinth 120 
were detected [23]. According to the available literature and a detailed analysis of their 
results, the authors propose that the mouse placenta produces haematopoietic 
stem/progenitor cells and primitive erythrocytes perhaps were involved or responsible for a 
rapid, mid-pregnancy, foetal growth trajectory. They also suggest that it may be a close 
origin of haematopoietic and endothelial cells in the mouse placenta. Furthermore, the 125 
findings described by this group indicate that placental erythropoietic foci arise in situ 
rather than from circulating cells. The possibility that precursors may generate into 
haematopoietic and endothelial cells ending in the formation of new vessels (i.e. 
angiogenesis) in the placenta is discussed. In another topic, Dr Chiarello and colleagues 
highlighted the fact that administering Mg2+ salts to women with preeclampsia is a routine 130 
procedure in clinical practice with an aim to reduce the pathophysiological consequences of 
preeclampsia and eclampsia [24]. In women with preeclampsia, Mg2+ sulphate and Mg2+ 
gluconate had been used, thereby resulting in the relaxation of the vascular smooth muscle 
perhaps because of an increase in NO synthesis due to stabilisation of the cofactor for 
endothelial NO synthase tetrahydrobiopterin and prevention of its oxidation. Several 135 
mechanisms are currently proposed for the beneficial effects of Mg2+ sulphate and are listed 
in Table 1 in the review. Interestingly, the expression of Mg2+ transporters such as 
Na+/Mg2+ exchangers (coded by SLC41A1) is increased in preeclampsia and a 
transplacental transfer of this cation is seen. Indeed, the trophoblast may contain lower 
levels of Mg2+ owing to hyperactivity of these and other membrane transporters. In general, 140 
it is proposed that Mg2+ restores endothelial dysfunction seen in preeclampsia, thereby 
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inactivating brain N-methyl-D-aspartate receptors and reducing the inflammatory response 
and oxidative stress. The information discussed in this review is summarized in Figure 1.  
 
Conclusions  145 
As PGMO and diabetes mellitus are metabolic alterations whose worldwide 
prevalence is increasing in the last decade, studies regarding the consequences of these 
conditions in placental function and foetal development are required. This series of review 
articles is a sample of the mechanisms involved in placental development and the 
consequences of an adverse intrauterine environment for the developing foetus. These 150 
changes result in a programming phenomenon that is transduced into diseases in the 
newborn, childhood, adolescence and adulthood. Equally, the mother presents post-
pregnancy diseases including diabetes mellitus and hypertension. The mechanisms 
associated with insulin resistance may include a restructuration of the functioning of the 
pancreas by inducing trans-differentiation of pancreatic α to β cells; these phenomena may 155 
cause or also be dependent on epigenetic modifications in the diseases of pregnancy. A 
factor always present in the metabolic adaptations in the placenta and the whole body is a 
proper oxidative stress balance between pro- and anti-oxidative mechanisms. The placenta 
has to adapt to these changes in pathologies such as preeclampsia and GDM. One of the 
mechanisms is angiogenesis, perhaps with the generation of new endothelial cells from 160 
placental haematopoietic cells, for supplying more efficiently the constant demand of 
nutrients or salts needed for proper development (such as Mg2+) by the growing foetus. 
Therefore, the gestation period is commanded by the healthiness of the placenta, and both 
the mother and the foetus communicate to make this process a successful one. 
165 
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